Avelumab is a fully human IgG1 monoclonal antibody that selectively binds to PD-L1; Chen et al. investigated the efficacy of this antibody in a cohort of patients affected by relapsed/refractory cHL. Here, CD274 is linked to classic Hodgkin lymphoma.